$8.38
0.00% yesterday
Nasdaq, Aug 21, 10:05 pm CET
ISIN
US09058V1035
Symbol
BCRX

BioCryst Pharmaceuticals, Inc. Stock price

$8.38
-0.14 1.64% 1M
-0.83 9.01% 6M
+0.86 11.44% YTD
+0.37 4.62% 1Y
-5.60 40.06% 3Y
+4.22 101.20% 5Y
-3.61 30.11% 10Y
+1.18 16.39% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.00 0.00%
ISIN
US09058V1035
Symbol
BCRX
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$2.2b
Net debt
$470.0m
Cash
$260.0m
Shares outstanding
209.9m
Valuation (TTM | estimate)
P/E
negative | 74.3
P/S
3.2 | 2.8
EV/Sales
4.0 | 3.6
EV/FCF
3,184.5
P/B
negative
Financial Health
Equity Ratio
-97.1%
Return on Equity
18.7%
ROCE
19.4%
ROIC
36.5%
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$557.5m | $621.8m
EBITDA
$55.5m | $101.7m
EBIT
$54.2m | $109.2m
Net Income
$-35.7m | $23.7m
Free Cash Flow
$700.0k
Growth (TTM | estimate)
Revenue
45.9% | 38.0%
EBITDA
194.3% | 7,926.2%
EBIT
189.9% | 4,399.2%
Net Income
75.5% | 126.7%
Free Cash Flow
100.8%
Margin (TTM | estimate)
Gross
97.0%
EBITDA
10.0% | 16.4%
EBIT
9.7%
Net
-6.4% | 3.8%
Free Cash Flow
0.1%
More
EPS
$-0.2
FCF per Share
$0.0
Short interest
12.4%
Employees
580
Rev per Employee
$780.0k
Show more

Is BioCryst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

BioCryst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from BioCryst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
558 558
46% 46%
100%
- Direct Costs 17 17
184% 184%
3%
541 541
44% 44%
97%
- Selling and Administrative Expenses 315 315
34% 34%
57%
- Research and Development Expense 171 171
15% 15%
31%
55 55
194% 194%
10%
- Depreciation and Amortization 1.28 1.28
13% 13%
0%
EBIT (Operating Income) EBIT 54 54
190% 190%
10%
Net Profit -36 -36
76% 76%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about BioCryst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCryst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 16 hours ago
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
Neutral
GlobeNewsWire
11 days ago
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Neutral
GlobeNewsWire
16 days ago
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock. The options and ...
More BioCryst Pharmaceuticals, Inc. News

Company Profile

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

Head office United States
CEO Jon Stonehouse
Employees 580
Founded 1986
Website www.biocryst.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today